...
首页> 外文期刊>Translational Oncology >Decentralization of Next-Generation RNA Sequencing-Based MammaPrint? and BluePrint? Kit at University Hospitals Leuven and Curie Institute Paris
【24h】

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint? and BluePrint? Kit at University Hospitals Leuven and Curie Institute Paris

机译:分散基于下一代RNA测序的MammaPrint?和BluePrint?鲁汶大学医院和巴黎居里研究所的试剂盒

获取原文
   

获取外文期刊封面封底 >>

       

摘要

A previously developed and centrally validated MammaPrint? (MP) and BluePrint? (BP) targeted RNA next-generation sequencing (NGS) kit was implemented and validated in two large academic European hospitals. Additionally, breast cancer molecular subtypes by MP and BP RNA sequencing were compared with immunohistochemistry (IHC). Patients with early breast cancer diagnosed at University Hospitals Leuven and Curie Institute Paris were prospectively included between September 2017 and January 2018. Formalin-fixed paraffin-embedded tissue sections were analyzed with MP and BP NGS technology at the beta sites and with both NGS and microarray technology at Agendia. Raw NGS data generated on Illumina MiSeq instruments at the beta sites were interpreted and compared with NGS and microarray data at Agendia. MP and BP NGS molecular subtypes were compared to surrogate IHC breast cancer subtypes. Equivalence of MP and BP indices was determined by Pearson's correlation coefficient. Acceptable limits were defined a priori, based on microarray data generated at Agendia between 2012 and 2016. The concordance, the Negative Percent Agreement and the Positive Percent Agreement were calculated based on the contingency tables and had to be equal to or higher than 90%. Out of 124 included samples, 48% were MP Low and 52% High Risk with microarray. Molecular subtypes were BP luminal, HER2 or basal in 82%, 8% and 10% respectively. Concordance between MP microarray at Agendia and MP NGS at the beta sites was 91.1%. Concordance of MP High and Low Risk classification between NGS at the beta sites and NGS at Agendia was 93.9%. Concordance of MP and BP molecular subtyping using NGS at the beta sites and microarray at Agendia was 89.5%. Concordance between MP and BP NGS subtyping, and IHC was 71.8% and 76.6%, for two IHC surrogate models. The MP/BP NGS kit was successfully validated in a decentralized setting.
机译:以前开发并经过中央验证的MammaPrint? (MP)和BluePrint? (BP)靶向RNA下一代测序(NGS)试剂盒已在两家欧洲大型学术医院实施并得到验证。此外,通过MP和BP RNA测序将乳腺癌分子亚型与免疫组织化学(IHC)进行了比较。在2017年9月至2018年1月期间,预期包括在鲁汶大学医院和巴黎居里研究所诊断为早期乳腺癌的患者。使用MP和BP NGS技术在β位点以及NGS和微阵列分析福尔马林固定石蜡包埋的组织切片Agendia的技术。解释了在Illumina MiSeq仪器的beta位置生成的原始NGS数据,并将其与Agendia的NGS和微阵列数据进行了比较。比较MP和BP NGS分子亚型与替代IHC乳腺癌亚型。 MP和BP指数的等效性由Pearson相关系数确定。可接受的限制是根据Agendia在2012年至2016年之间生成的微阵列数据预先定义的。一致性,负百分比协议和正百分比协议是根据意外事件表计算得出的,且必须等于或高于90%。在124个样本中,有48%的MP低和52%的高风险微阵列。分子亚型分别为BP管腔,HER2或基础型,分别为82%,8%和10%。 Agendia的MP芯片与β位点的MP NGS之间的一致性为91.1%。 β位点的NGS与Agendia的NGS之间的MP高危和低危分类的一致性为93.9%。在β位点使用NGS和Agendia的微阵列对MP和BP分子亚型的一致性为89.5%。对于两个IHC替代模型,MP和BP NGS亚型与IHC之间的一致性分别为71.8%和76.6%。 MP / BP NGS试剂盒已在分散环境中成功验证。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号